New York, New York--(Newsfile Corp. - February 17, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ: MEDP) concerning potential violations of the federal securities laws.

On February 10, 2026, Medpace shares fell approximately 10% by mid-day and closed down 15.9%, according to data from Quiver Quantitative and GuruFocus. Approximately $10.2 million in trading volume was recorded during the sell-off, reflecting heightened activity well above normal daily averages. The decline occurred despite the company reporting Q4 revenue of $708.5 million and GAAP EPS of $4.67, both of which exceeded Wall Street consensus estimates. Medpace underperformed the broader Nasdaq-100 and the CRO sector, which were flat to modestly positive on the same trading day.

Analyst and financial media commentary was nearly unanimous in identifying the cause. Investor's Business Daily called the bookings shortfall the "key negative" that overwhelmed the sales and profit beat. Seeking Alpha reported the stock dropped over 15% because the book-to-bill ratio missed expectations. GuruFocus noted a "sharp decline" in stock price raising investor concerns about forward demand. Finviz published an analysis focused on cancellations and metabolic-trial mix pressure on margins.

Institutional activity around the earnings date added further context. Principal Financial Group reduced its Medpace stake by 8.4% in a filing disclosed on February 8, 2026, just one day before the earnings release. Meanwhile, Representative David Taylor (R-OH) purchased shares on February 2, 2026, according to MarketBeat. The timing of these transactions relative to the earnings disclosure is relevant to the investigation.

During the Q4 earnings call, several sell-side analysts pressed management on the nature of the booking deterioration. Christine Rains of William Blair asked about direct-fee growth embedded in guidance. Justin Bowers of Deutsche Bank sought to quantify RFP activity and characterize cancellations by therapeutic area and customer. Ann Hynes of Mizuho asked whether the cancellation level was historically unprecedented, to which management responded that, comparing to the prior year, "it was the highest level of cancellations out of backlog." David Windley of Jefferies questioned whether metabolic concentration could drive further cancellations. Charles Rhyee of TD Cowen asked whether cancellations were driven by funding constraints or trial failure. CEO Troendle's responses described cancellations as "broad-based" and involving "no single large project," leaving investors without any clear answers.

If you suffered a loss on your Medpace Holdings, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284221

Source: Levi & Korsinsky, LLP